drugset / Trial / NCT06561620
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).
Timeline
- Start
- 2024-05-01
- Primary completion
- 2027-05-01
- Completion
- 2029-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Befotertinib | Small molecule | — | Oral |
Indications
No indication recorded.